C. Daniel Myers - Jun 22, 2023 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role: Director
Signature: /s/ Eric Trachtenberg, Attorney-in-Fact
Stock symbol: KALA
Transactions as of: Jun 22, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/23/2023, 08:00 PM
Previous filing: Jun 2, 2023
Next filing: Aug 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALA	Common Stock	Award	$0	+3.78K	+230.73%	$0.00	5.42K	Jun 22, 2023	Direct	F1, F2
transaction	KALA	Common Stock	Award	$0	+1.1K	+20.28%	$0.00	6.52K	Jun 22, 2023	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALA	Stock Option (right to buy)	Award	$0	+5.05K		$0.00	5.05K	Jun 22, 2023	Common Stock	5.05K	$14.56	Direct	F5
transaction	KALA	Stock Option (right to buy)	Award	$0	+2.5K		$0.00	2.5K	Jun 22, 2023	Common Stock	2.5K	$14.56	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
F2	Includes 5,424 unvested RSUs.
F3	Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.
F4	Includes 6,524 unvested RSUs.
F5	This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.
F6	This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.